

Table S1. Baseline characteristics (n=254)

Characteristics	Number (%)
Median age (range) (year)	62 (20-91)
Sex	
Female	99 (39)
Male	155 (61)
M stage	
M1a	51 (20)
M1b	57 (22)
M1c	96 (38)
M1d	41 (16)
M0 (unresectable stage III)	9 (4)
Melanoma subtype	
Cutaneous	150 (59)
Acral	37 (15)
Mucosal	25 (10)
Ocular	12 (5)
Unknown primary	30 (12)
LDH	
Normal	135 (53)
Elevated	108 (43)
NA	11 (4)
Mutation	
BRAF	68 (27)
NRAS	46 (18)
KIT	11 (4)
Triple wild type*	100 (39)
NA	29 (11)
Prior treatment	
I.O. (including IL-2 & ipilimumab)	99 (39)
Targeted therapy (MAPKi)	30 (12)
Chemo	61 (24)
Other targeted therapy (KITi, mTORi, etc.)	14 (6)
None	95 (37)
Anti-PD-1 antibody	
Pembrolizumab	198 (78)
Nivolumab	20 (8)
Camrelizumab	36 (14)

NA, not available. *Wild type for BRAF, NRAS and KIT genes.